Objectives: Although mechanical ventilation is a life-saving measure for patients in respiratory failure, prolonged mechanical ventilation results in diaphragmatic weakness attributable to fiber atrophy and contractile dysfunction. Therefore, identifying the signaling pathways responsible for mechanical ventilation-induced diaphragmatic weakness is important. In this context, it is established that oxidative stress is required for mechanical ventilation-induced diaphragmatic weakness to occur. Numerous redox-sensitive signaling pathways exist in muscle including the transcription factor nuclear factor-B. Although it has been suggested that nuclear factor-B contributes to proteolytic signaling in inactivity-induced atrophy in locomotor muscles, the role that nuclear factor-B plays in mechanical ventilation-induced diaphragmatic weakness is unknown. We tested the hypothesis that nuclear factor-B activation plays a key signaling role in mechanical ventilation-induced diaphragmatic weakness and that oxidative stress is required for nuclear factor-B activation.
M echanical ventilation (MV)
is used clinically to provide sufficient alveolar ventilation in patients incapable of maintaining adequate pulmonary gas exchange. For patients with acute respiratory failure, MV is a life-saving intervention. Unfortunately, MV results in a rapid development of respiratory muscle weakness, which is predicted to contrib-ute to weaning problems from MV (1, 2) . Weaning difficulties are a dilemma in critical care medicine because 20%-30% of MV patients experience weaning problems (3) . Therefore, understanding the mechanism leading to MV-induced diaphragmatic weakness is important.
In reference to cell signaling pathways that lead to MV-induced diaphragm weakness, it is clear that MV results in the rapid development of diaphragmatic oxidative stress (4 -6) . Avoidance of MVinduced oxidative damage via antioxidants can protect the diaphragm from MV-induced atrophy and contractile dysfunction (6 -8) . Specifically, our work reveals that oxidative stress is required for the activation of several key proteolytic systems involved in MV-induced diaphragmatic atrophy (e.g., calpain and caspase-3) (7, 9) . These findings indicate that the MV-induced production of reactive oxygen species in the diaphragm is an essential upstream trigger for signaling events that lead to diaphragm weakness.
In regard to specific redox-sensitive signaling pathways that contribute to locomotor skeletal muscle proteolysis, the transcriptional activating factor nuclear factor-kappa B (NF-B) has been suggested to play a significant role. Specifically, the NF-B signaling pathway promotes the expression of a key protein associated with the ubiquitin-protease system of proteolysis (i.e., E3 ligase, muscle ring finger-1) and NF-B activation is an important contributor to disuseinduced atrophy in locomotor skeletal muscles (10, 11) . Activation of NF-B is achieved through nuclear transport of dimers of NF-B family members and often occurs by the ubiquitination and degradation of the inhibitory protein Ikap-paB (IB), which otherwise binds NF-B heterodimers and retains their cytosolic residence (10, 11) . Although evidence indicates that NF-B contributes to locomotor muscle catabolism during disuse, the role that NF-B plays in MV-induced diaphragmatic atrophy remains un-known. Therefore, these experiments determined if NF-B activation is required for MV-induced diaphragm atrophy/ contractile dysfunction. We also established if oxidative stress is essential for MV-induced activation of NF-B in the diaphragm. Based on our preliminary results, we hypothesized that NF-B activation contributes to MV-induced diaphragm atrophy and contractile dysfunction and that oxidative stress is essential for NF-B activation in the diaphragm during prolonged MV.
MATERIALS AND METHODS

Animals and Experimental Design
Animals were obtained from Charles River Laboratories, Wilmington, MA. Young adult (approximately 4 -6 months old) female Sprague-Dawley rats were randomly assigned to one of four experimental groups (n ϭ 8 per group): acutely anesthetized control; 12 hrs of controlled MV (12MV); 12 hrs of MV treatment with the NF-B-specific inhibitor SN50 (12MV-SN50); and 12 hrs of MV treatment with the antioxidant curcumin. The Institutional Animal Care and Use Committee of the University of Florida approved these experiments.
Experimental Protocol
MV. All surgical procedures were performed using aseptic techniques. Animals in the MV groups were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg body weight), tracheostomized, and administered MV with a pressure-controlled ventilator (Servo Ventilator 300; Siemens, Munich, Germany) for 12 hrs with the following settings: upper airway pressure limit, 10 cm H 2 O; respiratory rate, 80 bpm; positive end-expiratory pressure, 1 cm H 2 O.
The carotid artery was cannulated to permit the continuous measurement of blood pressure and the collection of blood during the protocol. Arterial blood samples (100 L per sample) were removed periodically and analyzed for arterial PO 2 , PCO 2 , and pH using an electronic blood gas analyzer (GEM Premier 3000; Instrumentation Laboratory, Lexington, MA). Ventilator adjustments were made if arterial PCO 2 exceeded 40 mm Hg. Furthermore, arterial PO 2 was maintained Ͼ60 mm Hg throughout the experiment by increasing the FIO 2 (22%-26% oxygen).
A venous catheter was inserted into the jugular vein for continuous infusion of sodium pentobarbital (approximately 10 mg/kg/ hr). Body temperature was maintained at 37°C by use of recirculating heating blankets, and heart rate was monitored via a lead II electro-cardiograph. Continuous care during the MV protocol included lubricating the eyes, expressing the bladder, removing airway mucus, rotating the animal, and passively moving the limbs. Animals also received an intramuscular injection of glycopyrrolate (0.04 mg/kg) every 2 hrs during MV to reduce airway secretions. On completion of MV, the diaphragm was quickly removed and a strip of the medial costal diaphragm was used for in vitro contractile measurements, a section was stored for histochemical analyses, and the remaining portion was frozen in liquid nitrogen and stored at Ϫ80°C for subsequent analyses.
SN50 Administration. The p50 inhibitor, SN50 was administered at 10 g/kg (Calbiochem, San Diego, CA) 12 hrs before surgery (12, 13) . This dose was chosen based on previous animal studies showing that in vivo administration of SN50 at this dose inhibits NF-B activity by blocking the nuclear localization sequence on p50 (12, 13) .
Curcumin Administration. The antioxidant curcumin (Cayman, Ann Arbor, MI) was administered using three intraperitoneal doses (600 mg/kg), one 24 hrs before surgery, one 12 hrs before surgery, and one immediately before surgery. This specific dose was chosen based on previous studies demonstrating the effectiveness of curcumin administration in blocking NF-B by scavenging reactive oxygen intermediates that can activate NF-B over a range of doses (14) .
Biochemical Measures
Western Blot Analysis. Protein abundance was determined in diaphragm samples via Western blot analysis. Briefly, diaphragm tissue samples were homogenized 1:10 (weight/ volume) in 5 mM Tris (pH 7.5) and 5 mM EDTA (pH 8.0) with a protease inhibitor cocktail (Sigma, St. Louis, MO) and centrifuged at 1500g for 10 mins at 4°C. After collection of the resulting supernatant, diaphragmatic protein content was assessed by the method of Bradford (Sigma). Proteins from the supernatant fraction were separated via polyacrylamide gel electrophoresis via 4%-20% gradient polyacrylamide gels containing 0.1% sodium dodecyl sulfate for approximately 1 hr at 200 V. Nonspecific sites were blocked for 2 hrs at room temperature in phosphatebuffered saline solution containing 0.05% Tween and 5% nonfat milk. Membranes were then incubated overnight at 4°C with primary antibodies directed against the protein of interest. 4-Hydroxynoneal (4-HNE; Abcam, Cambridge, MA) was probed as a measurement indicative of oxidative stress. Proteolytic activity was assessed by analyzing cleaved (active) calpain-1 (Cell Signaling) and cleaved (active) caspase-3 (Cell Signaling). Furthermore, a-II spectrin (Santa Cruz Biotechnology, Santa Cruz, CA) calpain-specific cleavage (145-kDa cleavage product) and caspase-3-specific cleavage (120-kDa cleavage product) were measured to obtain an additional measurement of both calpain-1 and caspase-3 activity during MV. Last, measurements were made of Atrogin-1 and MuRF-1 (ECM Biosciences, Versailles, KY) as markers of proteasome activity. Bax and Bcl-2 (Abcam) were measured as markers of NF-B transcription activity. IB-␣ (Santa Cruz Biotechnology) protein levels were measured to assess NF-B activity. After incubation with primary antibodies, membranes were washed extensively with phosphate-buffered saline Tween and then incubated with secondary antibodies (GE Healthcare, Piscataway, NJ). After washing, a chemiluminescent system was used to detect labeled proteins (GE Healthcare). Membranes were developed using autoradiography film and images of the film were captured and analyzed using the 440CF Kodak Imaging System (Kodak, New Haven, CT). In addition, membranes were stripped and reprobed for ␣-tubulin (Santa Cruz Biotechnology), which served as a loading control. ␣-Tubulin protein concentration was also quantified using the 440CF Kodak Imaging System (Kodak) and used to normalize proteins by dividing them by the corresponding tubulin concentration.
RNA Isolation and CDNA Synthesis. Total RNA was isolated from muscle tissue with TRIzol Reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Total RNA and RNA content (g/mg muscle) were evaluated by spectrophotometry. Total RNA (5 g) was then reverse-transcribed with the Superscript III First-Strand Synthesis System for reverse-transcription polymerase chain reaction (Life Technologies) using oligo(dT)20 primers and the protocol outlined by the manufacturer.
Real-Time Polymerase Chain Reaction. One microliter of cDNA was added to a 25-L polymerase chain reaction for real-time polymerase chain reaction using Taqman chemistry and the ABI Prism 7000 Sequence Detection system (Applied Biosystems, Foster City, CA). Relative quantification of gene expression was performed using the comparative computed tomography method (Applied Biosystems, User Bulletin no. 2, ABI PRISM 7700 Sequence Detection System). This method uses a single sample, the calibrator sample (␤-glucuronidase; GenBank NM Y00717, NM M13962), for comparison of the gene expression of every unknown sample. The ⌬⌬CT[⌬CT(calibrator)-⌬CT(sample)] was then calculated for each sample and relative quantification was calculated as 2⌬⌬CT. ␤-Glucuronidase, a lysosomal glycoside hydrolase, was chosen as the reference gene based on previous work showing unchanged expression with our experimental manipulations (15, 16) . Five-fold dilution curves were assayed on selected samples to confirm the validity of this quantification method for each gene. MAFbx, MuRF-1, and Nedd4 messenger (mRNA) transcripts were assayed using predesigned rat primer and probe sequences commercially available from Applied Biosystems (Assays-on-Demand). The sequences used by the manufacturer in the design of primers and probes from this service are proprietary and are, therefore, not reported, after (Assays-on-Demand) in the text.
20S Proteasome Activity. A section of the ventral costal diaphragm was homogenized 1:10 (volume:volume) (5 mM Tris-HCL, pH ϭ 7.5; 5 mM EDTA, pH ϭ 8.0) and centrifuged at 1500g for 10 mins (4°C). Cytosolic fraction was centrifuged at 10,000g for 10 mins (4°C), followed by an additional spin of the supernatant at 100,000g for 1 hr (4°C). The in vitro chymotrypsin-like activity of the 20S proteasome was measured fluorometrically using techniques described by Stein et al (17) .
p50 Activity. Cellular fractionation of diaphragm tissue was performed according to Alway et al (18) . Diaphragmatic p50 DNA binding was measured in the nuclear protein fraction according to manufacturer's instructions using a commercially available NF-B transcription factor kit (Thermo Scientific, Rockford, IL).
Measurement of In Vitro Diaphragmatic Contractile Properties. On kill or the completion of the MV period, the entire diaphragm was removed and placed in a dissecting chamber containing a Krebs-Henseleit solution equilibrated with 95% O 2 -5% CO 2 gas. A muscle strip, including the tendinous attachments at the central tendon and rib cage, was dissected from the mid costal region. The strip was suspended vertically between two lightweight Plexiglas clamps with one end connected to an isometric force transducer (model FT-03; Grass Instruments, Quincy, MA) within a jacketed tissue bath. The force output was recorded via a computerized data acquisition system (Super Scope II; GW Instruments Somerville, MA; Apple Computer, Cupertino, CA). The tissue bath was filled with Krebs-Henseleit saline and the buffer was aerated with gas (95% O 2 -5% CO2), pH was maintained at 7.4, and the osmolality of the bath was approximately 290 mosmol/kgH 2 O. After a 15-min equilibration period (25°C), in vitro diaphragmatic contractile measurements were made. The muscle strip was stimulated along its entire length with platinum wire electrodes (modified S48 stimulator; Grass Instruments) by using supramaximal (approximately 150%) stimulation voltage to determine the optimum contractile length. Contractile length was de-termined by systematically adjusting the length of the muscle using a micrometer while evoking single twitches. Thereafter, all contractile properties were measured isometrically at contractile length. To measure maximal isometric twitch force, each strip was stimulated supramaximally with 120-V pulses at 1 Hz, and to measure the force frequency response each strip was stimulated supramaximally with 120-V pulses at 15-160 Hz. The duration of each train was 500 msecs to achieve a force plateau. Contractions were separated by a 2-min recovery period. For comparative purposes, diaphragmatic (bundles of fibers) force production was normalized as specific arterial O 2 and arterial PO 2 . The total muscle cross-sectional area at right angles to the long axis was calculated by the following algorithm (19) : total muscle cross-sectional area (mm 2 ) ϭ [muscle mass/(fiber length ϫ 1.056)], where 1.056 is the density of muscle (g/cm 3 ). Fiber length was expressed in centimeters measured at contractile length (20) .
Histologic Measures
Myofiber Cross-Sectional Area. Sections from frozen diaphragm samples were cut at 10 microns using a cryotome (Shandon, Pittsburgh, PA) and stained for dystrophin, myosin heavy chain I, and myosin heavy chain type IIa proteins for fiber cross-sectional area analysis as described previously (9) . Cross-sectional area was determined using Scion software (NIH).
Statistical Analysis
Comparisons between groups for each dependent variable were made by a one-way analysis of variance and, when appropriate, a Tukey honestly significant difference test was performed post hoc. Significance was established at p Ͻ .05. Data are presented as means Ϯ SD.
RESULTS
Systemic and Biological Response to MV
Before the initiation of MV, no significant differences existed in body weight between the groups (control ϭ 288 g Ϯ 4; 12MV ϭ 295 g Ϯ 5; 12MV-SN50 ϭ 304 g Ϯ 5; and 12MV with curcumin ϭ 286 g Ϯ 5). Importantly, 12 hrs of MV did not significantly alter body weight of the MV, MV-SN50, or MVC group (p Ͻ .05). Note that heart rate and systolic blood pressure were maintained relatively constant during the 12 hrs of MV and no significant differences existed between experimental groups in any of these measures at the completion of 12 hrs of MV ( Table 1 ). The PaO 2 and PaCO 2 were also maintained relatively constant during MV, with no significant differences existing between groups (Table 1 ). In addition, the colonic (body) temperature was also maintained (36°C-37°C) during the MV period. At the completion of the MV protocols, there were no visual abnormalities of the lungs or peritoneal cavity, no visible indication of lung injury, and no evidence of infection, indicating that our aseptic surgical technique was successful.
NF-B Activity
The NF-B family of transcription factors is activated during conditions of disuse locomotor skeletal muscle atrophy. We measured p50 DNA binding in the diaphragm as a marker of NF-B activation. Our results indicate that p50 activity is increased during MV, and that both SN50 and curcumin treatment attenuate the increase in p50 activation (Fig. 1A) .
Because IB-␣ binds NF-kB family members, preventing dimerization and activation, we also measured diaphragmatic levels of IB-␣ after MV. Prolonged MV resulted in a significant decrease in diaphragmatic levels of IB-␣, indicating that IB-␣ was being degraded and providing further support that NF-B is activated in the diaphragm during MV (Fig.  1B) . Treatment with SN50 or curcumin decreased degradation of IB-␣ in the diaphragm. In addition, the ratio of the pro-apoptotic protein Bax to the antiapoptotic protein Bcl-2 was assessed to evaluate abundance of these two NF-B gene targets. Although not statistically significant, diaphragmatic levels of Bax tended to increase during MV, whereas Bcl-2 levels tended to decrease. However, the ratio of Bax to Bcl-2 in the diaphragm was significantly increased during MV compared to both controls and animals treated with the antioxidant curcumin and the NF-B inhibitor, SN50 ( Fig. 2 A-C) . Values are means Ϯ SD. Note that no significant differences existed between the two experimental groups in any of these physiologic variables.
Ubiquitin-Proteasome System
The ubiquitin-proteasome system of proteolysis is activated in the diaphragm during prolonged MV and, therefore, is predicted to contribute to MV-induced diaphragmatic protein breakdown. To determine the effect of NF-B inhibition on the activity of the ubiquitin-proteasome system in the diaphragm, we measured 20S proteasome activity along with both mRNA and protein levels of the muscle-specific E3 ligases (i.e., atrogin-1/ MAFbx and MuRF-1) in the diaphragm. Our results reveal that both SN50 and curcumin administration during MV prevented the increase in 20S proteasome activity in the diaphragm (Fig. 3A) . We also observed a significant MV-induced increase in mRNA levels of the E3 ligase Nedd4 in the diaphragm, and curcumin administration was sufficient to attenuate this expression ( Fig. 3B ). Additionally, our data indicate that prolonged MV re-sulted in a significant increase in both diaphragm atrogin-1/MaFbx and MuRF-1 mRNA and protein levels ( Fig. 3C-F) . Treatment with SN50 significantly blunted the increase in MuRF-1 mRNA and protein levels in the diaphragm but did not attenuate MVinduced increases in atrogin-1 mRNA and protein levels. Finally, curcumin administration attenuated increases in 20S proteasome activity along with the increases in mRNA and proteins levels of both atrogin-1 and MuRF-1 in the diaphragm.
Calpain and Caspase-3 Activity
Previous work by our group indicates that calpain and caspase-3 activation in the diaphragm plays an important role in MVinduced diaphragm weakness (7, 9) . Therefore, we determined whether SN50 or curcumin treatment affected either calpain or caspase-3 activity in the diaphragm during MV. Treatment with curcumin significantly attenuated MV-induced increases in calpain activation; however, calpain activity remained significantly higher than control levels with SN50 treatment during MV (Fig.  4A ). In addition, both SN50 and curcumin treatment significantly attenuated increases in diaphragmatic caspase-3 activity during MV (Fig. 4B ). To confirm these results, we also measured calpain and caspase-3-specific cleavage of ␣-II spectrin (Fig. 4C, D) . These results were in general agreement with our direct measures of calpain and caspase-3 activity and provide confirmatory evidence regarding the impact of SN50 and curcumin on MV-induced activation of calpain and caspase-3 in the diaphragm.
Oxidative Stress
The efficacy of curcumin to prevent MVinduced diaphragmatic oxidative stress was determined by measuring a biomarker of lipid peroxidation. 4-HNE is formed during the lipid peroxidation cascade and 4-HNE/ protein adducts are an excellent biomarker of lipid peroxidation in tissue. Compared to control, 12 hrs of MV resulted in a significant increase in diaphragmatic 4-HNE/ protein adducts (Fig. 5 ). Curcumin administration significantly attenuated the MVinduced accumulation of 4-HNE/protein adducts in the diaphragm. We interpret these findings as evidence that curcumin administration effectively inhibits MVinduced diaphragmatic oxidative stress. In contrast, treatment of animals with SN50 did not significantly prevent MV-induced oxidative stress in the diaphragm, as evidenced by the significant increase in 4-HNE/protein adducts (Fig. 5 ).
MV-Induced Diaphragmatic Contractile Dysfunction
To evaluate diaphragmatic contractile dysfunction, we measured both the in vitro maximal isometric twitch force and forcefrequency responses in strips of diaphragm muscle. Compared to control, 12 hrs of MV significantly shifted the force-frequency response down and to the right at all stimulation frequencies (Fig. 6 ). Prevention of NF-B activation via SN50 treatment protected the diaphragm against MV-induced contractile dysfunction at stimulation frequencies Ͼ60 Hz. Further, treatment with 
MV-Induced Diaphragm Myofiber Atrophy
Myofiber cross-sectional area was determined for individual fiber types in diaphragm muscle strips from all treatment groups. Prolonged MV resulted in significant atrophy of type I, type IIa, and type IIb/IIx diaphragm myofibers. Importantly, treatment of animals with both SN50 and curcumin significantly attenuated MV-induced atrophy of type 1 and type IIa diaphragm myofibers (Fig. 7) . Finally, curcumin attenuated the MV-induced decrease in type IIb/x diaphragm fibers, but SN50 failed to protect these fibers against atrophy.
DISCUSSION
Overview of Principle Findings
These experiments provide new and important findings relative to the signaling pathways responsible for the rapid onset of MV-induced diaphragm atrophy and contractile dysfunction. Specifically, our results are the first to establish the importance of NF-B activation in MVinduced diaphragm weakness and to support the hypothesis that NF-B signaling contributes to MV-induced diaphragmatic atrophy and contractile dysfunction. Further, our findings corroborate our prediction that MV-induced oxidative stress is required for MV-induced NF-B activation in the diaphragm. Importantly, our discovery that the antioxidant curcumin is protective against both MVinduced oxidative stress and diaphragmatic weakness may have clinical implications regarding the use of curcumin or similar compounds to protect the diaphragm during prolonged MV.
NF-B Activation Contributes to MV-Induced Diaphragm Atrophy and Contractile Dysfunction
NF-B represents a family of five transcription factors, and active NF-B dimers can be formed by various combinations of these family members. It is well-known that muscle disuse leads to increased transcriptional activity of NF-B (10, 11) . Extensive work by Kandarian et al (10, 21, 22) has shown that knockout of either p50 or the co-transactivator Bcl-3 is sufficient to rescue skeletal muscle from disuse-induced atrophy. Specifically, the transcription factors p50 and Bcl-3 appear to be essential for atrophy during periods of skeletal muscle disuse (21) . In this regard, the role that NF-B plays in MV-induced diaphragmatic atrophy is unknown and thus formed the rationale for the current experiments. To determine the importance of NF-B in MV-induced diaphragmatic weakness, we utilized the synthetic peptide SN50 to inhibit nuclear translocation of the NF-B family member p50. We hypothesized that NF-B activation and signaling contributes to MV-induced diaphragm atrophy and contractile dysfunction, and our results support this postulate.
The current investigation, along with many previous studies, has shown that prolonged MV results in a rapid development of diaphragmatic atrophy (5, 7, (23) (24) (25) (26) . Specifically, numerous studies indicate that 12 hrs of MV is sufficient to result in increased biomarkers of oxidative damage, decreased contractile function, and decreased muscle fiber cross-sectional area in the rat diaphragm (5, (7) (8) (9) 25) . This rapid MV-induced diaphragm atrophy is attributable to a decrease in protein synthesis and the rapid increase in proteolysis that occurs in the diaphragm during MV (5, 27) . By comparison to the time course of disuseinduced proteolysis in limb skeletal muscle, MV-induced proteolysis in the diaphragm occurs at a much earlier time point (28) .
Importantly, our results show that inhibition of NF-B activation via SN50 administration was sufficient to attenuate the MV-induced decrease in diaphragm muscle fiber cross-sectional area of both type I and type IIa fibers. In contrast, inhibition of NF-B did not protect against MV-induced atrophy of diaphragm type IIb/x fibers. Future studies are necessary to examine why the type I and type IIa fibers were selectively protected. In addition, inhibiting NF-B activation resulted in only a partial protection of MV-induced diaphragmatic contractile dysfunction. Hence, although our results indicate that NF-B signaling contributes to MV-induced weakness in the diaphragm, our findings reveal that NF-B activation alone is not solely responsible for the signaling pathways leading to diaphragmatic weakness during prolonged MV. In this regard, our current and previous work suggests that activation of proteases (e.g., calpain and caspase-3) are also involved in MVinduced diaphragmatic atrophy and contractile dysfunction (7, 9) .
It appears likely that NF-B activity contributes to muscle atrophy because of its ability to transcribe specific atrophy-related genes. When activated, NF-B rapidly enters the nucleus and promotes gene transcription. Specifically, NF-B activity is responsible for the transcription of many pro- apoptotic and anti-apoptotic factors (i.e., Bax and Bcl-2) and the E3 ligases Nedd4 and MuRF-1 (10, 11, 29, 30) . Bax is a proapoptotic protein that can promote mitochondrial outer membrane pore opening, leading to the release of cytochrome c and activation of caspase-3. Bcl-2 is an antiapoptotic protein, and increases in the Baxto-Bcl-2 ratio are often used as a biomarker of the vulnerability of mitochondria to trigger apoptosis (31) . Furthermore, the proteasome system plays an important role in muscle wasting because of its ability to degrade polyubiquitinated proteins; this augmented degradation of polyubiquitinated proteins is attributable, in part, to the increased expression of two muscle-specific ubiquitin ligases, atrogin-1 and MuRF-1 (14) . Our data reveal that during MV, there is a significant increase in both the Bax-to-Bcl-2 ratio and caspase-3 activation in the diaphragm. Importantly, our findings reveal that treatment of animals with either NF-B inhibitor (i.e., SN50) or antioxidant (i.e., curcumin) was sufficient to inhibit both the MV-induced increase in the Baxto-Bcl-2 ratio and caspase-3 activation in the diaphragm. Furthermore, MV promoted an increased expression of Nedd4, Atrogin-1, and MuRF-1 in the diaphragm. This effect was inhibited by the antioxidant curcumin, whereas inhibition of NF-B activation attenuated MuRF-1 and Nedd4 ex-pression but did not protect against Atrogin-1 expression in the diaphragm.
Oxidative Stress Is Required for NF-B Activation in the Diaphragm During Prolonged MV
It is clear that MV-induced oxidative stress is required for MV-induced diaphragmatic weakness (4, 5, 32) . More specifically, our previous work reveals that MV-induced oxidative stress is a requirement for both the diaphragmatic atrophy and contractile dysfunction that is associated with prolonged MV (6, 8) . Further, we also have shown that MVinduced oxidative stress is essential for the activation of numerous proteases in the diaphragm, including calpain and caspase-3 (6, 7). Activation of calpain and caspase-3 in the diaphragm is significant because both proteases are important contributors to MV-induced diaphragmatic proteolysis and weakness (9, 33) .
Although NF-B signaling has been shown to be sufficient and required for normal muscle wasting during disuse-induced skeletal muscle atrophy, before the current experiments it was unknown if MV-induced diaphragmatic oxidative stress acts as an upstream regulator of NF-B signaling during MV (10, 11) . Our results support the hypothesis that MV-induced oxidative stress in the diaphragm is required for NF-B activation and reveal that treatment of animals with the potent polyphenolic antioxidant curcumin protects against oxidative damage and prevents NF-B activation in the diaphragm during MV. Although the current experiments do not reveal the mechanism behind this protection, it is possible that curcumin prevents NF-B activation by inhibiting IB-␣ phosphorylation and degradation by the proteasome (6, 34) . It is also possible that curcumin may inhibit MV-induced diaphragmatic NF-B activation by preventing calpain and caspase-3 activation (7) . Both active calpain and caspase-3 also have been shown to cleave IB-␣ to activate NF-B (35, 36) . Therefore, it is possible that the proteasome, calpain, and caspase-3 all may play an important role in NF-B activation, and that curcumin prevents MV-induced diaphragmatic NF-B activation by preventing proteasome, calpain, and caspase-3 activation.
Curcumin Protects Against MV-Induced Diaphragmatic Weakness
Notably, in addition to attenuating oxidative damage and NF-B activation in the diaphragm during MV, treatment of animals with the antioxidant curcumin protected against the MV-induced decreases in diaphragm muscle fiber cross-sectional area and contractile dysfunction. Further, curcumin protected against MV-induced diaphragm contractile dysfunction at frequencies Ͼ30 Hz. It is unclear why curcumin failed to protect the diaphragm at lower stimulation frequencies. Finally, these results are consistent with previous results indicating that the antioxidant trolox is also capable of preventing MVinduced diaphragmatic weakness (4, 6 -8) . The finding that curcumin protects against MV-induced diaphragmatic weakness has clinical implications and suggests that this compound could have therapeutic potential in the prevention of MV-induced diaphragmatic weakness.
In regard to the possible clinical application of curcumin in patients undergoing MV, a recent review has concluded that curcumin is safe to humans even in high doses (approximately 2-12 g) (37) . Furthermore, curcumin administration is associated with few unpleasant side effects in patients (38) . Finally, curcumin administration to human appears safe over an extended period of time; therefore, extended administration of cur- 
